Core Viewpoint - The article highlights the advancements in marine biomedicine in Qingdao, particularly focusing on the clinical trials of the marine polysaccharide drug BG136, which is the first of its kind in the world to enter clinical trials for cancer treatment [5][15]. Marine Biomedical Research - The Qingdao Marine Biomedical Research Institute aims to bridge the gap between scientific research and industrial application in marine biomedicine, promoting the transformation of research outcomes into marketable products [5][6]. - BG136, derived from Antarctic seaweed, activates the innate immune system to exert anti-tumor effects [6][15]. - The institute is also advancing other projects under the "Blue Pharmacy" initiative, including new drugs for chronic obstructive pulmonary disease (COPD) and hepatitis B, as well as an HPV treatment that has already been launched [6][15]. Industry Development - The Qingdao Marine Biomedical Research Institute is part of a broader strategy to create an integrated ecosystem for marine biomedical innovation, combining government, industry, academia, and finance [7]. - The marine biomedical industry in Qingdao is expected to exceed 38 billion yuan in output by 2024, with projections to reach a scale of 100 billion yuan by 2026 [15]. - The city has established a "4+2+4" marine industry system to foster emerging sectors, including marine pharmaceuticals and bio-products, while enhancing traditional industries [13][15]. Competitive Advantage - China's marine drug research capabilities rank among the top globally, with domestically developed marine drugs accounting for 28% of the global market [15]. - Qingdao has nurtured leading companies in the marine pharmaceutical sector, contributing to the formation of significant industry clusters in marine drugs, medical dressings, and health products [15].